Hexarelin 5mg

Hexarelin is a synthetic hexapeptide research compound studied for its potential to stimulate growth hormone secretion. Designed for laboratory and research applications, this 5mg formulation offers precise dosing for controlled experimental protocols. Each vial contains pharmaceutical-grade material suitable for in vitro and animal model studies. Hexarelin has been the subject of scientific investigation into growth hormone dynamics and metabolic pathways. Ideal for researchers and institutions requiring high-purity peptide compounds for advanced studies.

Peptide Sequence: His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2 Molecular Weight: 886.04 g/mol Purity: ≥98% (HPLC) Physical Form: Lyophilized powder Vial Size: 5mg per vial Storage: Keep refrigerated at 2–8°C. Protect from light and moisture. Reconstitution: Dissolve in sterile water or bacteriostatic saline for injection. Research Applications: Growth hormone secretion studies, metabolic research, neuroendocrine investigations. Quality Assurance: Manufactured to pharmaceutical standards with certificate of analysis provided.

Molecular Formula: C49H66N12O9 CAS Number: 140703-51-1 Empirical Composition: Carbon, hydrogen, nitrogen, and oxygen in hexapeptide structure with D-amino acid modifications. Structural Classification: Synthetic growth hormone-releasing peptide (GHRP) analogue.

Before Reconstitution (Lyophilized Powder): Store at 2–8°C in original sealed vial. Keep in a cool, dark place away from direct sunlight and moisture. Unopened vials remain stable for 24 months when stored properly. Avoid repeated temperature fluctuations. After Reconstitution (Solution): Once dissolved in sterile water or bacteriostatic saline, use immediately for optimal stability. If storage is necessary, keep reconstituted solution at 2–8°C for up to 7 days. For extended storage beyond one week, freeze at −20°C or below. Thaw at room temperature before use. Avoid multiple freeze-thaw cycles. Do not store at room temperature for extended periods.

Research References

The following peer-reviewed studies and publications are provided for informational and scientific reference purposes only. They do not constitute medical claims or endorsements of this product for any therapeutic use.

1. Hexarelin: Discovery and GH-Releasing Activity
   Deghenghi R, et al. (1994). GH-releasing activity of Hexarelin, a new growth hormone releasing peptide, in infant and adult rats. Life Sciences, 54(18), 1321–1328. https://doi.org/10.1016/0024-3205(94)90031-0
   Original characterisation of hexarelin as a potent synthetic GHRP, demonstrating robust GH-releasing activity in both infant and adult rat models and establishing its pharmacological profile relative to GHRP-6.
2. Hexarelin and GHS-R1a Receptor Binding
   Muccioli G, et al. (1998). Identification and characterization of a novel growth hormone-releasing peptide receptor in the rat brain and liver. Neuroendocrinology, 67(4), 232–237. https://doi.org/10.1159/000054319
   Identifies and characterises the GHS-R1a receptor binding profile of hexarelin in rat brain and hepatic tissue, providing mechanistic insight into its central and peripheral GH-secretory actions.
3. Cardioprotective Effects of Hexarelin in Animal Models
   Bisi G, et al. (1999). Hexarelin, a synthetic growth hormone-releasing peptide, improves cardiac function in rats with myocardial infarction. European Journal of Pharmacology, 381(2–3), 135–141. https://doi.org/10.1016/S0014-2999(99)00572-4
   Demonstrates hexarelin-mediated improvements in cardiac contractility and haemodynamic parameters in a rat myocardial infarction model, independent of GH release, suggesting direct cardiac receptor-mediated effects.
4. Hexarelin and CD36 Receptor Interaction
   Demers A, et al. (2004). Hexarelin protects against atherosclerotic lesion development in apolipoprotein E-deficient mice. Endocrinology, 145(2), 551–558. https://doi.org/10.1210/en.2003-0686
   Identifies CD36 as a non-GHS-R binding target for hexarelin and demonstrates attenuation of atherosclerotic lesion development in ApoE-deficient mice, expanding the mechanistic scope of hexarelin research beyond the GH axis.
5. Neuroendocrine and Metabolic Effects of Hexarelin
   Arvat E, et al. (1997). Hexarelin, a synthetic GH-releasing peptide, stimulates GH, ACTH, cortisol and prolactin secretion in humans. Journal of Clinical Endocrinology & Metabolism, 82(7), 2439–2444. https://doi.org/10.1210/jcem.82.7.4055
   Characterises the neuroendocrine secretory profile of hexarelin in human subjects, documenting stimulation of GH alongside ACTH, cortisol, and prolactin — distinguishing its broader hypothalamic–pituitary axis activity from more selective GHRPs such as ipamorelin.

All references are cited for scientific context only. This product is supplied strictly for in vitro laboratory research. It is not approved for human or veterinary use.